Financial Comparison: 3SBio (SSRX) vs. Its Competitors
3SBio (NASDAQ: SSRX) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare 3SBio to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.
This is a summary of current ratings and target prices for 3SBio and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
3SBio has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, 3SBio’s competitors have a beta of 1.03, meaning that their average stock price is 3% more volatile than the S&P 500.
Valuation & Earnings
This table compares 3SBio and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|3SBio Competitors||$564.12 million||$96.17 million||40.99|
3SBio’s competitors have higher revenue and earnings than 3SBio. 3SBio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
43.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares 3SBio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
3SBio beats its competitors on 6 of the 11 factors compared.
3SBio Inc. is a biotechnology company in the People’s Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Receive News & Ratings for 3SBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.